Aryl hydrocarbon receptor

Study Illustrates Zeropollution's Enhancing Skin's Resilience to Environmental Damage

Retrieved on: 
Tuesday, March 5, 2024
Quercetin, Lippia, Air pollution, Woman, Capsule, Elasticity, Doctor of Philosophy, Oleuropein, Rosmarinus, Aryl hydrocarbon receptor, Inflammation, Free-radical theory of aging, Pollution, HPLC, Heart rate, Skin, Volunteering, Molecular biology, Radiation, Health, Lipid peroxidation, Caturla, Hesham Tillawi, Sophora, Drink, Reactive oxygen species, Journal, Clinical trial, Oxidative stress, ROS, Endothelium, Tissue, Núria, Antioxidant, DNA, Beauty, Dietary supplement

MADRID, March 5, 2024 /PRNewswire/ -- A new, preclinical study highlights the abilities of a beauty-from-within botanical-blend Zeropollution® to shield skin from the adverse effects of city pollution, especially from free radical damage on a cellular level.

Key Points: 
  • This patented multi-herbal cosmeceutical has been crafted to synergistically strengthen the skin's protective barrier against environmental insults through an "inside out" approach.
  • The study led by Laurent Peno-Mazzarino was published in the Journal of Current Issues in Molecular Biology in January 2024.
  • This encompasses reactive molecules generated by factors such as UV radiation, pollution, and other environmental stressors that can damage cells and tissues.
  • In this study, Zeropollution successfully counteracted the adverse effects of urban dust on the heart rate of zebra fish embryos.

MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Pharmaceutical, Health, Bone marrow, Annual general meeting, Charcot disease, European Medicines Agency, Maat, ICI, HSCT, Randomized controlled trial, CFO, ASH, Artificial intelligence, EMA, Patient, DSMB, PICASSO, Medi-Cal Access Program, Aryl hydrocarbon receptor, Hematopoietic stem cell transplantation, Immunotherapy, EUR, Therapy, Symantec Endpoint Protection, ORR, Cancer, Survival, MET, SITC, ARES, CGMP, Development, Society, Pharmaceutical industry, Vaccine, ALS

We are proud to achieve these milestones and we will continue to work on generating value for our shareholders,” stated Siân Crouzet, CFO of MaaT Pharma.

Key Points: 
  • We are proud to achieve these milestones and we will continue to work on generating value for our shareholders,” stated Siân Crouzet, CFO of MaaT Pharma.
  • MaaT Pharma reported revenues from its compassionate access program of EUR 0.4 million for the quarter ended September 30, 2023 comparable with the third quarter of 2022.
  • 2 The Company would like to correct a clerical error that was present in its Q2 results press release of July 27, 2023.
  • The EUR 0.9 million figure was the difference in revenue between H1 2023 and H1 2022 (EUR 1.4 million vs. EUR 0.5 million).

Bayer Presents New Data Across Oncology Portfolio at the 2023 ASCO Annual Meeting

Retrieved on: 
Thursday, May 25, 2023
Pharmaceutical, Health, Oncology, Docetaxel, Thyroid, Observational study, Mutation, ADT, Radium, Science, ASCO, DEAR, American Society of Clinical Oncology, Metastasis, Patient, NTRK, Annual general meeting, Disease, Copanlisib, RWE, Radium-223, FDA, Aryl hydrocarbon receptor, Safety, Society, ORR, TC, Enza, TRK, Medical imaging, Pharmaceutical industry, Daro District, Bayer

Bayer will highlight scientific research in oncology at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting , taking place from June 2-6, 2023.

Key Points: 
  • Bayer will highlight scientific research in oncology at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting , taking place from June 2-6, 2023.
  • These presentations continue to underscore the company’s commitment to drive treatment approaches through science and innovation in the oncology space.
  • Data featuring NUBEQA® (darolutamide) and Xofigo® (radium Ra 223 dichloride) will be showcased at ASCO.
  • NUBEQA data includes results from the DEAR trial, a retrospective, observational study evaluating real-world evidence (RWE) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

NCPDP Announces Robin Farmanfarmaian as Keynote Speaker for its 2023 Annual Technology & Business Conference, "The Great Race to Close Gaps in Care"

Retrieved on: 
Wednesday, February 22, 2023
Organization, White, Health, Pharmacy, Robin, Department of Defence, United States Department of Defense, Aryl hydrocarbon receptor, VR, Diagnosis, Patient, Organ, The Patient, Database, Silicon, White House, Morphine, Early Bird, Knowledge, Great race, Meeting, Drug discovery, Quality of life, Book, The Westin Kierland Resort & Spa, Conference, NCPDP, Cryopreservation, Pharmaceutical industry, Health care

SCOTTSDALE, Ariz., Feb. 22, 2023 /PRNewswire-PRWeb/ -- NCPDP announced today Robin Farmanfarmaian, speaker, author, and tech entrepreneur, will give an important closing keynote address about the future of healthcare, technology, and patient empowerment at NCPDP's 2023 Annual Technology & Business Conference, "The Great Race to Close Gaps in Care", May 8-10, 2023, at the Westin Kierland Resort & Spa in Scottsdale, Arizona. NCPDP's national annual conference draws more than 700 attendees from across the healthcare industry, including technical, business, and executive representatives from health plans, pharmacy benefit managers, retail and independent pharmacies, specialty pharmacies, long-term care providers, healthcare consultants, technology vendors, pharmaceutical manufacturers, wholesale drug distributors, database management organizations and others.

Key Points: 
  • Medical Tech Futurist, Robin Farmanfarmaian, Will Engage and Inspire Conference Goers in a Powerful Call to Action to Close Gaps in Healthcare.
  • SCOTTSDALE, Ariz., Feb. 22, 2023 /PRNewswire-PRWeb/ -- NCPDP announced today Robin Farmanfarmaian, speaker, author, and tech entrepreneur, will give an important closing keynote address about the future of healthcare, technology, and patient empowerment at NCPDP's 2023 Annual Technology & Business Conference, "The Great Race to Close Gaps in Care" , May 8-10, 2023, at the Westin Kierland Resort & Spa in Scottsdale, Arizona.
  • Robin Farmanfarmaian, who lives, breathes, and works on the cutting edge of all things medical technology, has an incredible story to share.
  • For real-time updates before and during the event, follow us at http://twitter.com/ncpdp or join the discussion using NCPDP's 2023 Annual Technology & Business Conference hashtag: #NCPDP23.

Dermavant Launches First Commercial for VTAMA® (tapinarof) cream, 1% as Part of a National, Multimedia Campaign for Adults with Plaque Psoriasis

Retrieved on: 
Tuesday, November 22, 2022
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Itch, Inflammatory bowel disease, Marketing, Cell, Groin, Neck, Irritation, Multimedia, Headache, Body surface area, Empathy, Face, Journal of Dermatological Treatment, Risk, Human, Aryl hydrocarbon receptor, Itchy, Folliculitis, Obesity, Research, Depression, Progress, Pain, Hypertension, Smoking, NPA, Incidence, Stinger, FDA, Psoriasis, Common, Atopic dermatitis, National Psoriasis Foundation, Swelling, Rash, Genetics, Roivant Sciences, Therapy, Diabetes, Dermatology, Food, Veni, vidi, vici, Calendar, Skin, Injection, Nose, Prescription, Weather, Inflammation, Gesellschaft mit beschränkter Haftung, Patient, Pharmaceutical industry, Cosmetics, Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology

Many have been waiting a long time for a different plaque psoriasis treatment like VTAMA cream.

Key Points: 
  • Many have been waiting a long time for a different plaque psoriasis treatment like VTAMA cream.
  • The commercial gives topical plaque psoriasis patients aka the silent majority a voice, empowering them to demand more from their topical plaque psoriasis treatment and truly feel heard.
  • Indication: VTAMA (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
  • Plaque psoriasis, also called psoriasis vulgaris, is the most common form and affects about 80 to 90% of people with psoriasis.

INDIGO Biosciences Receives Approval from California Water Boards for Use of Its Bioassays in Recycled Water Monitoring

Retrieved on: 
Tuesday, November 15, 2022
Health, Aryl hydrocarbon receptor, Environment, Estradiol, California State Water Resources Control Board, ER, Water, CECS, Hydrocarbon, Estrogen, INDIGO, Cancer, Pesticide, CEO, Drug discovery, Science, Estrogen receptor alpha, Environmental remediation, Assay

STATE COLLEGE, Pa., Nov. 15, 2022  /PRNewswire-PRWeb/ -- INDIGO Biosciences, Inc. has received approval from the California Water Boards, State Water Resources Control Board, for the use of two of its bioassays in recycled water monitoring. INDIGO has been approved for the use of its Aryl Hydrocarbon Receptor (AhR) and Estrogen Receptor Alpha (ERα) bioassays as bioanalytical screening tools for Constituents of Emerging Concern (CECs) in recycled water.

Key Points: 
  • STATE COLLEGE, Pa., Nov. 15, 2022 /PRNewswire-PRWeb/ -- INDIGO Biosciences, Inc. has received approval from the California Water Boards, State Water Resources Control Board , for the use of two of its bioassays in recycled water monitoring.
  • INDIGO has been approved for the use of its Aryl Hydrocarbon Receptor (AhR) and Estrogen Receptor Alpha (ER) bioassays as bioanalytical screening tools for Constituents of Emerging Concern (CECs) in recycled water.
  • We look forward to developing additional bioassays that can help water boards and regulators everywhere monitor for contaminants that pose potential environmental and health risks."
  • As part of the approval process, INDIGO submitted validation packages for both its AhR and ER assays.

Dermavant Announces Highly Favorable Results from Pediatric Maximal Usage Study of VTAMA® (tapinarof) cream, 1% in Atopic Dermatitis

Retrieved on: 
Tuesday, November 8, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Cream, People, Shanda, AES, Face, Sleep, Neck, Atopic dermatitis, JD, NPA, Ageing, IGA, FDA, Patient, Swelling, Calendar, Population, Stinger, QD, Itchy, Disease, Irritation, Headache, Nose, Inflammation, Dermatitis, Pain, Aryl hydrocarbon receptor, Roivant Sciences, Folliculitis, Incidence, PK, Body surface area, Psoriasis, Itch, Fatigue, Gesellschaft mit beschränkter Haftung, Rash, Efficiency, Common, Marketing, Research, Skin, BSA, Therapy, Safety, Pharmacokinetics, Tachyphylaxis, Adult, Cosmetics, Vaccine, Pharmaceutical industry, MD

The studys objective was to characterize the pharmacokinetics (PK) and safety of VTAMA cream under maximal usage conditions in pediatric subjects with atopic dermatitis.

Key Points: 
  • The studys objective was to characterize the pharmacokinetics (PK) and safety of VTAMA cream under maximal usage conditions in pediatric subjects with atopic dermatitis.
  • The maximal usage study of VTAMA cream, 1% utilized the same dose and frequency (1% cream, applied QD) as is being studied in Dermavants ongoing ADORING 1 and ADORING 2 pivotal trials for atopic dermatitis.
  • VTAMA cream, 1% demonstrated favorable safety, PK and clinical improvement in atopic dermatitis in subjects down to 2 years of age.
  • Dermavant anticipates presenting the full data set from its maximal usage study of VTAMA cream, 1% in atopic dermatitis at a future medical meeting.

Dermavant to Present Data from Multiple Clinical Trials of VTAMA® (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference

Retrieved on: 
Thursday, October 13, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Cream, People, Stinger, LinkedIn, PASI, Therapy, Efficiency, Conference, Smoking, NPA, Dermatology Life Quality Index, Depression, Wynn's Hotel, Dublin, Nose, Treatment, Psoriasis, Irritation, Pharmacokinetics, Roivant Sciences, Rash, Inflammatory bowel disease, BSA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, QD, PGA, Pivotal, Folliculitis, Marketing, Quality of life, Obesity, Incidence, Aryl hydrocarbon receptor, Skin, FDA, Risk, DLQI, Hypertension, Body surface area, Research, Cell, Itchy, Headache, Gesellschaft mit beschränkter Haftung, Itch, Pain, AD, Genetics, Inflammation, Weather, Wynn Las Vegas, Disease, Patient, Food, Atopic dermatitis, Swelling, Safety, Diabetes, Common, Plasma, Calendar, Pharmaceutical industry, Cosmetics, Vaccine

Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced it will present data from multiple studies of VTAMA (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference from October 20-23 in Las Vegas.

Key Points: 
  • Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced it will present data from multiple studies of VTAMA (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference from October 20-23 in Las Vegas.
  • The poster presentations at the conference will include data on VTAMA cream for the treatment of plaque psoriasis in adults and atopic dermatitis in patients as young as two.
  • Indication: VTAMA (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
  • The FDA approved VTAMA cream for the topical treatment of mild, moderate, and severe plaque psoriasis in May 2022.

Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
LinkedIn, Squamous cell carcinoma, SEC, Head, Hippopotamus, SITC, Aryl hydrocarbon receptor, Patient, Twitter, Program, Annual general meeting, Immunotherapy, RAS, AHR, Cancer, Private Securities Litigation Reform Act, Tumor microenvironment, Nivolumab, Society, PD-1, 2021 Essex County Council election, Society for Immunotherapy of Cancer, GLOBE, Clinical trial, Bristol Myers Squibb, Immunology, TEAD, Pharmaceutical industry

IK-175 is an oral AHR antagonist designed to modulate the tumor microenvironment, increasing both innate and adaptive immunity.

Key Points: 
  • IK-175 is an oral AHR antagonist designed to modulate the tumor microenvironment, increasing both innate and adaptive immunity.
  • The initial results from the first-in-human Phase 1a/b clinical trial presented at SITC will include data from the dose-escalation cohorts and initial data from the urothelial carcinoma expansion cohorts.
  • Ikena Oncologyis focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer.
  • The Companys ongoing discovery research spans other targets in the Hippo pathway as well as the RAS signaling pathway.

Fortune and Great Place to Work® Name Dermavant One of the Best Small Workplaces™ and Best Workplaces in Biopharma™ in 2022

Retrieved on: 
Wednesday, September 7, 2022
Professional Services, Health, Human Resources, Other Science, Science, Pharmaceutical, Biotechnology, Inflammation, Great Places, Research, Calendar, Aryl hydrocarbon receptor, Daily Journal Corporation, Fortune, Skin, LinkedIn, Roivant Sciences, Psoriasis, Organization, Therapy, Atopic dermatitis, 100 Best Workplaces in Europe, Feedback, Efficiency, Management, Mail order, Therapure BioPharma Inc, Heart

To determine the Best Small Workplaces and Best Workplaces in Biopharma lists, Great Place to Work analyzed survey responses from more than 30,000 employees from Great Place to Work-Certified companies.

Key Points: 
  • To determine the Best Small Workplaces and Best Workplaces in Biopharma lists, Great Place to Work analyzed survey responses from more than 30,000 employees from Great Place to Work-Certified companies.
  • Dermavant also ranked as a Fortune Best Small Workplace in 2020 and 2021 and was ranked one of the Best Workplaces in Biopharma in 2021.
  • Great Place to Work selected the Best Small Workplaces by analyzing the survey responses of over 30,000 employees from Great Place to Work-Certified companies with 10 to 99 U.S. employees.
  • Great Place to Work selected the Best Workplaces in BioPharma by gathering and analyzing confidential survey responses from more than 36,000 employees at Great Place to Work-Certified organizations in the biopharma industry.